Journal article icon

Journal article

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

Abstract:

PURPOSE: One mechanism of tumor resistance to cytotoxic therapy is repair of damaged DNA. Poly(ADP-ribose) polymerase (PARP)-1 is a nuclear enzyme involved in base excision repair, one of the five major repair pathways. PARP inhibitors are emerging as a new class of agents that can potentiate chemotherapy and radiotherapy. The article reports safety, efficacy, pharmacokinetic, and pharmacodynamic results of the first-in-class trial of a PARP inhibitor, AG014699, combined with temozolomide in...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


Plummer, R More by this author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Oncology, Biomedical Research Centre
Expand authors...
Journal:
Clinical cancer research : an official journal of the American Association for Cancer Research
Volume:
14
Issue:
23
Pages:
7917-7923
Publication date:
2008-12-05
DOI:
EISSN:
1557-3265
ISSN:
1078-0432
URN:
uuid:064f2be5-62de-48e2-b9c6-765f3f56f4a6
Source identifiers:
119616
Local pid:
pubs:119616

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP